AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 241 min read$RCUS

Azoy Alexander sold $85K of RCUS

Azoy Alexander (Chief Accounting Officer) sold 2,827 shares of Arcus Biosciences, Inc. (RCUS) at $30.00 on 2026-08-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Azoy Alexander
Published Aug 24, 2026, 9:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 24, 2026, 9:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RCUS
Neutral
medium confidence
Mentioned
$RCUS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RCUSNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock significantly.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming clinical data could offset sell‑off concerns.

Relevance 2/10Novelty 4/10Timing: post‑market filing

Background

Form 4 filings disclose insider trades; a 10b5‑1 plan indicates pre‑arranged sales.

Company-level read

Ticker impact

$RCUSNeutralMedium confidence
Context

Chief Accounting Officer Azoy Alexander sold 2,827 shares for $84,810 under a 10b5‑1 plan, reducing his stake to 39,581 shares.

Expected impact

Potential modest downside as market perceives insider sell signal.

Evidence & confidence

The sale amount is small relative to market cap and likely reflects a pre‑arranged plan, limiting material impact.

Market effects

Sector

No broader sector impact; isolated insider transaction.

Regional

Limited to U.S. biotech investors.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

Insider sell may be routine; price could remain unchanged.

Key entities

  • Company
    Arcus Biosciences, Inc.

    Biotech firm developing cancer immunotherapies.

  • Person
    Azoy Alexander

    Chief Accounting Officer of Arcus Biosciences.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RCUS insider trading history →

Related articles

SEP 16
$RCUSHigh

Why is Arcus Biosciences stock rallying today?

Arcus Biosciences (RCUS) stock rose 3.4% after TD Cowen initiated coverage with a Buy rating, citing casdatifan's clinical profile. Analysts highlight its 15.1-month median progression-free survival vs. 5.6 months for Welireg. Arcus reported Q2 2026 revenue of $41M, beating estimates. The stock has a consensus Moderate Buy rating. Broader market gains also supported the move.

investing.com2 min
SEP 16
$RCUSMed

Arcus Biosciences stock gains on TD Cowen buy rating

Arcus Biosciences (RCUS) shares rose 3.4% after TD Cowen initiated coverage with a Buy rating. Analyst Tara Bancroft cited potential for casdatifan to lead in renal cell carcinoma treatment, noting its progression-free survival advantage over Welireg. Bancroft highlighted data that could derisk Phase III trials and position casdatifan in the $10B+ market.

investing.com1 min
AUG 5
$RCUSMed

Arcus Biosciences, Inc. (RCUS): Results of Operations and Financial Condition

Arcus Biosciences, Inc. (RCUS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update August 5, 2026 • Arcus executes on strategy to establish casdatifan as a backbone therapy across each line of treatment for clear cell renal cell carcinoma (ccRCC), includi

SEC EDGAR 8-K7 min